# Increased Mortality Associated with Amiodarone Compared to Other Antiarrhythmic Drugs in New-onset Atrial Fibrillation.

Yun Gi Kim, MD, PhD[1], Hyoung Seok Lee, MD[1], Hoseob Kim, MPH[2], Mina Kim, MS[2], Joo Hee Jeong, MD[1], Yun Young Choi, MD, PhD[1], Jaemin Shim, MD, PhD[1], Jong-Il Choi, MD, PhD, MHS, MSc[1]* and Young-Hoon Kim, MD, PhD[1]

[1]Division of Cardiology, Department of Internal Medicine, Korea University College of Medicine and Korea University Anam Hospital, Seoul, Republic of Korea

[2]Department of Data Science, Hanmi Pharm. Co., Ltd

*Address for correspondence: Jong-Il Choi, MD, PhD, MHS, MSc, FESC

[1]Division of Cardiology, Department of Internal Medicine, Korea University College of Medicine and Korea University Anam Hospital, Seoul, Republic of Korea

73 Goryeodae-ro, Seongbuk-gu, Seoul 02841, Republic of Korea

Tel: 82-2-920-5445 / Fax: 82-2-927-1478 / E-mail: jongilchoi@korea.ac.kr

**Running title:** Amiodarone and increased mortality

**Disclosure:** The authors have nothing to disclose.

**Total word count:** 767

Yun Gi Kim and Hyoung Seok Lee contributed equally to this work.

**Supplementary Table S1.** ICD-10 codes for atrial fibrillation.

| Code | Name |
|---|---|
| I48.0 | Paroxysmal atrial fibrillation |
| I48.1 | Persistent atrial fibrillation |
| I48.2 | Chronic atrial fibrillation |
| I48.9 | Atrial fibrillation and atrial flutter, unspecified |

ICD-10: international classification of diseases, 10th edition.

**Supplementary Table S2.** Drugs analyzed in this study.

| Type | Code | Name |
|---|---|---|
| Flecainide | 501902BIJ | Flecainide 150mg |
| | 501901BIJ | Flecainide 50mg |
| | 159301ATB | Flecainide acetate 100mg |
| | 159331BIJ | Flecainide acetate150mg (10mg/mL) |
| | 159302ATB | Flecainide acetate 50mg |
| | 159330BIJ | Flecainide acetate 50mg (10mg/mL) |
| Amiodarone | 107402BIJ | Amiodarone HCl 150mg |
| | 107430BIJ | Amiodarone hydrochloride 0.15g (50mg/mL) |
| | 107401ATB | Amiodarone hydrochloride 0.2g |
| Pilsicainide | 502101ACH | Pilsicainide HCl 25mg |
| | 502102ACH | Pilsicainide HCl 50mg |
| | 502101ACH | Pilsicainide hydrochloride 25mg |
| | 502102ACH | Pilsicainide hydrochloride 50mg |
| Propafenone | 219501ATB | Propafenone HCl 150mg |
| | 219503ACR | Propafenone HCl 225mg |
| | 219502ATB | Propafenone HCl 300mg |
| | 219504ACR | Propafenone HCl 325mg |
| | 219505ACR | Propafenone HCl 425mg |
| | 219501ATB | Propafenone hydrochloride 0.15g |
| | 219503ACR | Propafenone hydrochloride 0.225g |
| | 219504ACR | Propafenone hydrochloride 0.325g |
| | 219502ATB | Propafenone hydrochloride 0.3g |
| | 219505ACR | Propafenone hydrochloride 0.425g |
| Sotalol | 230401ATB | Sotalol HCl 160mg |
| | 230402ATB | Sotalol HCl 40mg |
| | 230402BIJ | Sotalol HCl 40mg |
| | 230403ATB | Sotalol HCl 80mg |
| Dronedarone | 597401ATB | Dronedarone 0.4g |

**Supplementary Table S3.** ICD-10 codes for various medical conditions.

| Covariates | Code | Name |
|---|---|---|
| Myocardial infarction | I21 | Acute myocardial infarction |
| | I22 | Subsequent myocardial infarction |
| | I23 | Certain current complications following acute myocardial infarction |
| Hypertension | I10 | Essential (primary) hypertension |
| | I11 | Hypertensive heart disease |
| | I12 | Hypertensive renal disease |
| | I13 | Hypertensive heart and renal disease |
| | I15 | Secondary hypertension |
| Diabetes mellitus | E10 | Type 1 diabetes mellitus |
| | E11 | Type 2 diabetes mellitus |
| | E12 | Malnutrition-related diabetes mellitus |
| | E13 | Other specified diabetes mellitus |
| | E14 | Unspecified diabetes mellitus |
| Dyslipidemia | E78 | Disorders of lipoprotein metabolism and other lipidemias |
| Hypo- or hyper-thyroidism | E03 | Other hypothyroidism |
| | E05 | Thyrotoxicosis [hyperthyroidism] |
| Stroke | I60 | Subarachnoid hemorrhage |
| | I61 | Intracerebral hemorrhage |
| | I62 | Other nontraumatic intracranial hemorrhage |
| | I63 | Cerebral infarction |
| | I64 | Stroke, not specified as hemorrhage or infarction |
| Heart failure | I50 | Heart failure |
| Chronic kidney disease | N18 | Chronic kidney disease |
| | N19 | Unspecified kidney failure |
| | Z49 | Persons encountering health services for care involving dialysis |
| | Z99.2 | Dependence on renal dialysis |

ICD-10: international classification of diseases, 10th edition.

**Supplementary Table S4.** Subgroup analysis.

| | Before PSM | | After PSM | |
|---|---|---|---|---|
| | **Hazard ration (95% confidence interval)** | **p value for interaction** | **Hazard ration (95% confidence interval)** | **p value for interaction** |
| **Age group** | | 0.599 | | 0.149 |
| 20 – 39 | NA | NA | NA | NA |
| 40 – 64 | 2.317 (1.815 – 2.958) | < 0.001 | 1.982 (1.439 – 2.729) | < 0.001 |
| 65 – | 2.947 (2.683 – 3.236) | < 0.001 | 2.850 (2.536 – 3.203) | < 0.001 |
| **Sex** | | 0.004 | | 0.002 |
| Male | 2.561 (2.283 – 2.872) | < 0.001 | 2.353 (2.039 – 2.716) | < 0.001 |
| Female | 3.388 (2.959 – 3.878) | < 0.001 | 3.383 (2.852 – 4.013) | < 0.001 |
| **Thyroid disease** | | 0.682 | | 0.636 |
| No | 2.875 (2.633 – 3.140) | < 0.001 | 2.743 (2.457 – 3.063) | < 0.001 |
| Yes | 3.385 (1.831 – 6.260) | < 0.001 | 3.478 (1.391 – 8.697) | 0.0077 |
| **Chronic kidney disease** | | 0.012 | | 0.161 |
| No | 2.953 (2.700 – 3.230) | < 0.001 | 2.811 (2.508 – 3.149) | < 0.001 |
| Yes | 1.912 (1.337 – 2.733) | < 0.001 | 2.002 (1.330 – 3.015) | < 0.001 |
| **Heart failure** | | 0.668 | | 0.447 |
| No | 2.871 (2.626 – 3.138) | < 0.001 | 2.722 (2.431 – 3.047) | < 0.001 |

| | | | | |
|---|---|---|---|---|
| Yes | 3.129 (2.028 – 4.828) | < 0.001 | 3.094 (1.967 – 4.866) | < 0.001 |
| **Myocardial infarction** | | 0.453 | | 0.641 |
| No | 2.872 (2.630 – 3.136) | < 0.001 | 2.742 (2.455 – 3.063) | < 0.001 |
| Yes | 3.736 (1.831 – 7.626) | < 0.001 | 3.323 (1.584 – 6.969) | 0.002 |
| **Diabetes mellitus** | | 0.033 | | 0.323 |
| No | 3.020 (2.734 – 3.337) | < 0.001 | 2.839 (2.502 – 3.221) | < 0.001 |
| Yes | 2.482 (2.076 – 2.967) | < 0.001 | 2.475 (1.986 – 3.084) | < 0.001 |
| **Dyslipidemia** | | 0.938 | | 0.652 |
| No | 2.893 (2.646 – 3.163) | < 0.001 | 2.765 (2.473 – 3.091) | < 0.001 |
| Yes | 2.701 (1.795 – 4.065) | < 0.001 | 2.518 (1.447 – 4.381) | 0.001 |
| **Hypertension** | | 0.629 | | 0.201 |
| No | 2.806 (2.484 – 3.171) | < 0.001 | 2.569 (2.212 – 2.983) | < 0.001 |
| Yes | 2.956 (2.611 – 3.348) | < 0.001 | 2.974 (2.532 – 3.493) | < 0.001 |

NA: not applicable; PSM: propensity-score matching. Hazard ratios were adjusted for age, sex, hypertension, diabetes mellitus, dyslipidemia, chronic kidney disease, heart failure, myocardial infarction, and thyroid disease.